Hospital
ST Marys Hospital of ST Marys County INC
ST Marys Hospital of ST Marys County INC was paid $3.54M by Medicaid between Jan 2018 and Dec 2024, across 84 billing codes. Its largest line is 41899, Unlisted procedure, dentoalveolar structures — 45% of everything it billed.
33Billing provider infoST MARYS HOSPITAL OF ST MARYS COUNTY INC
LEONARDTOWN, MD 20650
LEONARDTOWN, MD 20650
33aNPI1780650473assigned 02/23/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.54M
24GClaims92,576
24DCodes billed84
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maryland
Rank by total paid#15 of 69
Median peer was paid$870K
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,195 | $1.09M | |
| 2019 | 16,381 | $729K | |
| 2020 | 11,402 | $346K | |
| 2021 | 13,255 | $358K | |
| 2022 | 12,539 | $384K | |
| 2023 | 12,470 | $411K | |
| 2024incomplete | 8,334 | $222K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 41899 | Unlisted procedure, dentoalveolar structures | 45% | 378 | 353 | $1.58M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 3,103 | 2,614 | $531K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 4,821 | 4,113 | $526K |
| G0378 | Hospital observation service, per hour | 12% | 1,119 | 901 | $434K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 6.8% | 1,605 | 699 | $241K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.1% | 2,207 | 1,947 | $146K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,326 | 1,058 | $20K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 633 | 541 | $18K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 990 | 892 | $10K |
| 80053 | Comprehensive metabolic panel | <1% | 9,272 | 6,598 | $9K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 830 | 609 | $5K |
| 84484 | <1% | 5,244 | 3,730 | $5K |
72 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,121 | $3K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 118 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 106 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 491 | $2K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,703 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,604 | $1K |
| 81001 | <1% | 3,384 | $937.18 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 262 | $870.35 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,398 | $867.37 |
| 71045 | Radiologic examination, chest; single view | <1% | 4,089 | $692.42 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 888 | $681.27 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,469 | $675.42 |
| 87040 | <1% | 169 | $540.82 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 270 | $361.34 |
| 73562 | <1% | 51 | $331.76 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 137 | $323.42 |
| 83690 | <1% | 1,968 | $323.38 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,268 | $315.04 |
| 83735 | <1% | 4,723 | $309.09 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,519 | $308.54 |
| 87581 | <1% | 108 | $270.46 | |
| 93971 | <1% | 12 | $222.59 | |
| 82550 | <1% | 3,325 | $212.61 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,128 | $176.93 |
| 82553 | <1% | 1,120 | $167.49 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 244 | $121.86 |
| 83605 | <1% | 702 | $86.80 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 371 | $76.13 |
| 85379 | <1% | 315 | $72.95 | |
| J3490 | Unclassified drugs | <1% | 500 | $59.36 |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 61 | $48.79 |
| 85730 | <1% | 1,468 | $41.53 | |
| 94664 | <1% | 239 | $36.52 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 565 | $29.53 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 118 | $23.19 |
| 87070 | <1% | 39 | $22.86 | |
| 85610 | <1% | 2,186 | $22.37 | |
| 83880 | <1% | 709 | $16.32 | |
| 87428 | <1% | 35 | $6.50 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 712 | $4.30 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 127 | $4.12 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 296 | $0.66 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 459 | $0.46 |
| 84100 | <1% | 701 | $0.26 | |
| 87107 | 0% | 187 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 444 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 107 | $0.00 |
| 97161 | 0% | 13 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 101 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 388 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 18 | $0.00 |
| 85007 | 0% | 16 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
| 71250 | 0% | 12 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 44 | $0.00 |
| 84439 | 0% | 15 | $0.00 | |
| 87186 | 0% | 26 | $0.00 | |
| 86850 | 0% | 13 | $0.00 | |
| 94760 | 0% | 388 | $0.00 | |
| 87077 | 0% | 208 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 84 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 162 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 237 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 132 | $0.00 |
| 82077 | 0% | 13 | $0.00 | |
| 85027 | 0% | 16 | $0.00 | |
| 87205 | 0% | 29 | $0.00 | |
| 87486 | 0% | 20 | $0.00 | |
| 85651 | 0% | 13 | $0.00 | |
| 87280 | 0% | 14 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 17 | $0.00 |
| 97597 | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEISEL, MICHAEL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Medstar Southern Maryland Hospital Center INC | Clinton, MD | $18.35M |
| ST. Mary's Hospital of ST. Mary's County, INC. | Callaway, MD | $31K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.